Yip-Schneider M - Search Results

1

Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of the Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential.

Sans M, Makino Y, Min J, Rajapakshe KI, Yip-Schneider M, Schmidt CM, Hurd MW, Burks JK, Gomez JA, Thege FI, Fahrmann JF, Wolff RA, Kim MP, Guerrero PA, Maitra A. Sans M, et al. Among authors: yip schneider m. Cancer Discov. 2023 Aug 4;13(8):1844-1861. doi: 10.1158/2159-8290.CD-22-1200. Cancer Discov. 2023. PMID: 37285225 Free PMC article.

2

Inhibition of the phosphatidylinositol 3'-kinase signaling pathway increases the responsiveness of pancreatic carcinoma cells to sulindac.

Yip-Schneider MT, Wiesenauer CA, Schmidt CM. Yip-Schneider MT, et al. J Gastrointest Surg. 2003 Mar-Apr;7(3):354-63. doi: 10.1016/s1091-255x(02)00156-7. J Gastrointest Surg. 2003. PMID: 12654560

3

MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac.

Yip-Schneider MT, Schmidt CM. Yip-Schneider MT, et al. Pancreas. 2003 Nov;27(4):337-44. doi: 10.1097/00006676-200311000-00012. Pancreas. 2003. PMID: 14576498

4

Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.

Wiesenauer CA, Yip-Schneider MT, Wang Y, Schmidt CM. Wiesenauer CA, et al. J Am Coll Surg. 2004 Mar;198(3):410-21. doi: 10.1016/j.jamcollsurg.2003.10.004. J Am Coll Surg. 2004. PMID: 14992744

5

Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-kappa B pathway in pancreatic carcinoma cells.

Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM. Yip-Schneider MT, et al. Mol Cancer Ther. 2005 Apr;4(4):587-94. doi: 10.1158/1535-7163.MCT-04-0215. Mol Cancer Ther. 2005. PMID: 15827332

6

Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest.

Ralstin MC, Gage EA, Yip-Schneider MT, Klein PJ, Wiebke EA, Schmidt CM. Ralstin MC, et al. Mol Cancer Res. 2006 Jun;4(6):387-99. doi: 10.1158/1541-7786.MCR-05-0157. Mol Cancer Res. 2006. PMID: 16778086 Free article.

7

Cyclooxygenase-2 expression in hamster and human pancreatic neoplasia.

Crowell PL, Schmidt CM, Yip-Schneider MT, Savage JJ, Hertzler DA 2nd, Cummings WO. Crowell PL, et al. Neoplasia. 2006 Jun;8(6):437-45. doi: 10.1593/neo.04700. Neoplasia. 2006. PMID: 16820089 Free PMC article.

8

Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo.

Yip-Schneider MT, Wu H, Ralstin M, Yiannoutsos C, Crooks PA, Neelakantan S, Noble S, Nakshatri H, Sweeney CJ, Schmidt CM. Yip-Schneider MT, et al. Mol Cancer Ther. 2007 Jun;6(6):1736-44. doi: 10.1158/1535-7163.MCT-06-0794. Epub 2007 May 31. Mol Cancer Ther. 2007. PMID: 17541034

9

Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancer.

Vegeler RC, Yip-Schneider MT, Ralstin M, Wu H, Crooks PA, Neelakantan S, Nakshatri H, Sweeney CJ, Schmidt CM. Vegeler RC, et al. J Surg Res. 2007 Nov;143(1):169-76. doi: 10.1016/j.jss.2007.08.007. Epub 2007 Aug 31. J Surg Res. 2007. PMID: 17950089

10

Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-alpha-transgenic mice.

Wentz SC, Wu H, Yip-Schneider MT, Hennig M, Klein PJ, Sebolt-Leopold J, Schmidt CM. Wentz SC, et al. J Gastrointest Surg. 2008 Jan;12(1):30-7. doi: 10.1007/s11605-007-0396-4. Epub 2007 Nov 7. J Gastrointest Surg. 2008. PMID: 17987349

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

87 results

Search Page

Filters